Quantcast

Latest Quinazolines Stories

2008-10-12 18:00:07

A GRANDMOTHER with terminal cancer who faced moving to get life- saving drugs on the NHS has won her battle with Midland health bosses to receive her medication. Carol Rummels, from Stoke Lodge, in Bristol, considered moving to Scotland so she could continue to take the drug Tarceva. Doctors had given the 61 year-old just two months to live after diagnosing with brain and lung cancer last summer. But after taking the drug the tumours shrank, prolonging her life by another 12 months....

2008-10-12 18:00:07

A GRANDMOTHER with terminal cancer who faced moving to Scotland to get life-saving drugs free on the NHS has won her battle with health bosses in England to fund the medication that is keeping her alive. The landmark ruling means that other cancer sufferers in the area that may benefit from the drug will now be given Tarceva on the NHS. Carol Rummels, from Stoke Lodge, in Bristol, was given just two months to live after being diagnosed with brain and lung cancer last summer but after...

2008-10-06 21:00:15

By ; wire Shares of South San Francisco-based Genentech dropped nearly 8 percent after the company announced with OSI Pharmaceuticals that a combination of two cancer drugs, Avastin with Tarceva, missed its primary goal in a clinical trial, failing to improve survival for patients with late-stage lung cancer. The trial focused on patients who had not responded to chemotherapy. But patients who were treated with Avastin and Tarceva did not survive significantly longer than those who were...

2008-10-06 15:00:41

Blockbuster cancer drug Avastin has suffered a setback, failing to improve overall survival when added to Tarceva in a Phase III trial for second-line advanced non-small cell lung cancer. However, there may still be a future for the drug combination within this indication, assuming data from a Phase III trial in the maintenance setting prove more positive. The Phase III study, known as BeTa Lung, was a randomized, double blinded study comparing the second-line combination of Avastin...

2008-10-06 09:00:09

Genentech and OSI Pharmaceuticals have announced that a randomized Phase III study evaluating Avastin in combination with Tarceva in patients with advanced non-small cell lung cancer whose disease had progressed following platinum-based chemotherapy did not meet its primary endpoint of improving overall survival compared to Tarceva in combination with placebo. However, there was clear evidence of clinical activity with improvements in the secondary endpoints of progression-free survival and...

2008-10-06 03:00:07

Genentech, Inc. (NYSE:DNA) and OSI Pharmaceuticals, Inc. (Nasdaq:OSIP) today announced that a randomized Phase III study (BeTa Lung) evaluating Avastin(R) (bevacizumab) in combination with Tarceva(R) (erlotinib) in patients with advanced non-small cell lung cancer (NSCLC) whose disease had progressed following platinum-based chemotherapy did not meet its primary endpoint of improving overall survival compared to Tarceva in combination with placebo. However, there was clear evidence of...

2008-09-25 12:00:15

By Martin Eatock A new drug called Lapatinib was recently hailed a "big step forward" for women suffering from advanced breast cancer. Consultant medical oncologist at the Belfast City Hospital, Dr Martin Eatock, argues that its true impact could be limited Lapatinib, used in combination with the chemotherapy drug capecitabine, was recently licensed for the treatment of Her-2 positive advanced breast cancer, an aggressive form of the disease which affects around a quarter of those women...

2008-09-17 12:00:11

Chinese medical scientists say the drug gefitinib (Iressa) should be considered the first-line therapy for non-smoking Asian patients with lung cancer. Asia has a high proportion of lung cancer patients who are non-smokers, a significant proportion of whom develop a form of cancer known as adenocarcinoma. "Around 50 percent to 60 percent of this population (has tumors) with mutations in the epidermal growth factor receptor and we know that patients with such mutations have a significantly...

2008-07-14 09:00:14

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP) announced the publication of a study conducted by Cyclacel scientists showing synergistic activity between its investigational therapy seliciclib and multiple epidermal growth factor receptor (EGFR) inhibitors, including erlotinib (Tarceva(R)) in models of non-small cell lung cancer and the HER2 targeting agent, trastuzumab (Herceptin(R)) in models of breast cancer. These preclinical results were published in the July issue of the...

2008-07-08 12:00:16

The medical advisory panel to the UK National Health Service has recommended that GlaxoSmithKline's Tyverb should not be used on the NHS to treat advanced metastatic breast cancer on the grounds that it is not effective enough to justify its cost. This decision represents not only a blow to GSK but also casts doubt on how many other new cancer therapies will be available in the UK. The UK panel ruled that, based on data showing that the median survival time for women who received Tyverb...


Word of the Day
malpais
  • The ragged surface of a lava-flow.
'Malpais' translates from Spanish as 'bad land.'